Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Sparsentan vs. Irbesartan: The effectiveness of sparsentan in reducing proteinuria compared to irbesartan remains uncertain, as reported in the included study.
• Cyclosporin Effectiveness: Cyclosporin, with or without prednisone, may increase the likelihood of complete remission (RR 2.31, 95% CI 1.13 to 4.73) and complete or partial remission (RR 1.64, 95% CI 1.10 to 2.44) in patients with steroid-resistant FSGS. However, cyclosporin may not significantly increase the likelihood of partial remission alone (RR 1.36, 95% CI 0.78 to 2.39).
• Mycophenolate Mofetil (MMF): MMF compared with prednisone may not significantly impact the likelihood of achieving complete remission (RR 1.05, 95% CI 0.58 to 1.88) or partial remission in steroid-resistant FSGS.
• Cyclosporin Safety: Cyclosporin may have little or no effect on chronic kidney disease, kidney failure, hypertension, or infection outcomes when compared to other treatments. The safety of cyclosporin regarding these specific adverse outcomes remains uncertain.
• Mycophenolate Mofetil (MMF) Safety: MMF, compared to prednisone, may not significantly affect the likelihood of infection, as there was little to no difference observed between the two treatments.
• The systematic review included participants with steroid-resistant FSGS, but no additional information on other specific population types or subgroups (e.g., age, gender) was provided. There are no significant subgroup findings beyond those related to steroid-resistant FSGS.